Breaking News Instant updates and real-time market news.

HTGM

HTG Molecular

$1.14 /

+0.065 (+6.05%)

08:32
07/06/22
07/06
08:32
07/06/22
08:32

HTG Molecular releases whitepaper for transcriptome-informed approach

HTG Molecular Diagnostics has released a second white paper, further establishing the utility of its transcriptome-informed approach to drug design and discovery utilizing its proprietary HTG EdgeSeq technology. A cornerstone of HTG's Therapeutics business, the HTG Transcriptome Panel was launched with commercial availability in August of 2021. The HTP was designed to enable the assessment of approximately 20,000 mRNA targets using HTG's EdgeSeq technology, a targeted RNA sequencing technology that couples a nuclease protection assay with next-generation sequencing for rapid and accurate RNA quantification. HTG EdgeSeq's many advantages include a 96-well plate format, low sample input requirement, no RNA extraction, and rapid assay and analysis time. We believe these benefits make it an attractive technology for applying transcriptomic profiling to drug discovery. The White Paper describes the use of HTG's transcriptome-informed drug design and discovery platform in early-stage design, selection and characterization of small-molecule candidates for an initial therapeutic target. The results of the studies summarized in the White Paper revealed several indication-specific effects as well as potential undesirable effects of the initial therapeutic target through analysis of the transcriptomic profiles from compound-treated human cell line test systems.

OTHER BREAKING NEWS FROM THE FLY

Downgrade
K+S AG downgraded to Sector Perform from Outperform at Scotiabank » 08:07
08/12/22
08/12
08:07
08/12/22
08:07
KPLUY

K+S AG

$10.87 /

+0.28 (+2.64%)

, NTR

Nutrien

$90.51 /

+0.045 (+0.05%)

, CF

CF Industries

$101.91 /

+0.01 (+0.01%)

Scotiabank analyst Ben…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NTR Nutrien
$90.51 /

+0.045 (+0.05%)

CF CF Industries
$101.91 /

+0.01 (+0.01%)

KPLUY K+S AG
$10.87 /

+0.28 (+2.64%)

07/18/22 Morgan Stanley
K+S AG price target lowered to EUR 24 from EUR 26.50 at Morgan Stanley
05/12/22 Morgan Stanley
K+S AG price target raised to EUR 26.50 from EUR 20.50 at Morgan Stanley
05/12/22 Scotiabank
K+S AG price target raised to EUR 40 from EUR 38 at Scotiabank
04/20/22 DZ Bank
K+S AG downgraded to Hold from Buy at DZ Bank
NTR Nutrien
$90.51 /

+0.045 (+0.05%)

08/10/22 Barclays
Nutrien price target lowered to $105 from $126 at Barclays
08/09/22 Scotiabank
Nutrien upgraded to Outperform from Sector Perform at Scotiabank
07/18/22 RBC Capital
ITC ruling against U.S. UAN tariffs negative for CF Industries, says RBC Capital
07/14/22 Credit Suisse
Nutrien initiated with an Underperform at Credit Suisse
CF CF Industries
$101.91 /

+0.01 (+0.01%)

08/10/22 Barclays
CF Industries upgraded to Overweight from Equal Weight at Barclays
08/03/22 Scotiabank
CF Industries upgraded to Outperform from Sector Perform at Scotiabank
08/03/22 Citi
CF Industries upgraded to Buy on tighter ag conditions at Citi
08/03/22 Citi
CF Industries upgraded to Buy from Neutral at Citi
NTR Nutrien
$90.51 /

+0.045 (+0.05%)

CF CF Industries
$101.91 /

+0.01 (+0.01%)

CF CF Industries
$101.91 /

+0.01 (+0.01%)

NTR Nutrien
$90.51 /

+0.045 (+0.05%)

CF CF Industries
$101.91 /

+0.01 (+0.01%)

NTR Nutrien
$90.51 /

+0.045 (+0.05%)

CF CF Industries
$101.91 /

+0.01 (+0.01%)

Hot Stocks
SciSparc issued Israeli patent for tech treating CNS disorders » 08:07
08/12/22
08/12
08:07
08/12/22
08:07
SPRC

SciSparc

$1.19 /

-0.025 (-2.06%)

SciSparc announced it has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SPRC SciSparc
$1.19 /

-0.025 (-2.06%)

Recommendations
AppLovin price target lowered to $70 from $80 at DA Davidson » 08:06
08/12/22
08/12
08:06
08/12/22
08:06
APP

AppLovin

$34.46 /

-6.01 (-14.85%)

, U

Unity

$54.30 /

-1.21 (-2.18%)

DA Davidson analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
APP AppLovin
$34.46 /

-6.01 (-14.85%)

U Unity
$54.30 /

-1.21 (-2.18%)

APP AppLovin
$34.46 /

-6.01 (-14.85%)

08/11/22 BTIG
AppLovin price target lowered to $53 from $60 at BTIG
08/11/22 Truist
AppLovin price target lowered to $65 from $77 at Truist
08/11/22 Credit Suisse
ironSource downgraded to Neutral from Outperform at Credit Suisse
08/10/22 Citi
AppLovin bid for Unity faces 'several challenges,' says Citi
U Unity
$54.30 /

-1.21 (-2.18%)

08/11/22 Credit Suisse
ironSource downgraded to Neutral from Outperform at Credit Suisse
08/10/22 Citi
AppLovin bid for Unity faces 'several challenges,' says Citi
08/10/22 Oppenheimer
Unity price target raised to $60 from $54 at Oppenheimer
08/10/22 Benchmark
Benchmark keeps Sell rating on Unity, doesn't think AppLovin acquires
APP AppLovin
$34.46 /

-6.01 (-14.85%)

U Unity
$54.30 /

-1.21 (-2.18%)

  • 03
    Dec
APP AppLovin
$34.46 /

-6.01 (-14.85%)

U Unity
$54.30 /

-1.21 (-2.18%)

APP AppLovin
$34.46 /

-6.01 (-14.85%)

U Unity
$54.30 /

-1.21 (-2.18%)

APP AppLovin
$34.46 /

-6.01 (-14.85%)

U Unity
$54.30 /

-1.21 (-2.18%)

Hot Stocks
Terns Pharmaceuticals announces $65M oversubscribed offering » 08:06
08/12/22
08/12
08:06
08/12/22
08:06
TERN

Terns Pharmaceuticals

$2.40 /

+0.14 (+6.19%)

Terns Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TERN Terns Pharmaceuticals
$2.40 /

+0.14 (+6.19%)

TERN Terns Pharmaceuticals
$2.40 /

+0.14 (+6.19%)

03/23/22 JPMorgan
Terns downgraded after 'firmly negative' data at JPMorgan
03/23/22 JPMorgan
Terns Pharmaceuticals downgraded to Neutral from Overweight at JPMorgan
09/14/21 Goldman Sachs
Terns Pharmaceuticals assumed with a Buy at Goldman Sachs
TERN Terns Pharmaceuticals
$2.40 /

+0.14 (+6.19%)

TERN Terns Pharmaceuticals
$2.40 /

+0.14 (+6.19%)

Hot Stocks
Vontier appoints Anshooman Aga as CFO » 08:05
08/12/22
08/12
08:05
08/12/22
08:05
VNT

Vontier

$24.16 /

-0.315 (-1.29%)

, HSC

Harsco

$6.56 /

+0.04 (+0.61%)

Vontier (VNT) announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VNT Vontier
$24.16 /

-0.315 (-1.29%)

HSC Harsco
$6.56 /

+0.04 (+0.61%)

VNT Vontier
$24.16 /

-0.315 (-1.29%)

07/08/22 Barclays
Vontier price target lowered to $33 from $39 at Barclays
04/04/22 Barclays
Vontier price target lowered to $40 from $42 at Barclays
03/23/22 Argus
Vontier price target lowered to $30 from $40 at Argus
02/18/22 Citi
Vontier price target lowered to $34 from $39 at Citi
HSC Harsco
$6.56 /

+0.04 (+0.61%)

07/20/22 DA Davidson
Harsco price target lowered to $13 from $16 at DA Davidson
07/18/22 Barrington
Harsco price target lowered to $13 from $20 at Barrington
07/12/22 BMO Capital
Harsco initiated with a Market Perform at BMO Capital
05/04/22 Barrington
Harsco price target lowered to $20 from $22 at Barrington
VNT Vontier
$24.16 /

-0.315 (-1.29%)

HSC Harsco
$6.56 /

+0.04 (+0.61%)

Earnings
Checkpoint Therapeutics reports Q2 EPS (16c), consensus (17c) » 08:05
08/12/22
08/12
08:05
08/12/22
08:05
CKPT

Checkpoint Therapeutics

$1.26 /

+0.03 (+2.44%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CKPT Checkpoint Therapeutics
$1.26 /

+0.03 (+2.44%)

CKPT Checkpoint Therapeutics
$1.26 /

+0.03 (+2.44%)

07/14/22 B. Riley
Checkpoint Therapeutics resumed with a Buy at B. Riley
06/17/22 Lake Street
Checkpoint cosibelimab data 'competitive,' says Lake Street
06/07/22 Lake Street
Lake Street says Checkpoint warrants interest after cosibelimab 'shines' at ASCO
05/31/22 Cantor Fitzgerald
Cantor sees 'positive' data likely coming from Checkpoint Therapeutics in June
CKPT Checkpoint Therapeutics
$1.26 /

+0.03 (+2.44%)

CKPT Checkpoint Therapeutics
$1.26 /

+0.03 (+2.44%)

Hot Stocks
Longeveron expects cash to cover requirements into 1H24 » 08:04
08/12/22
08/12
08:04
08/12/22
08:04
LGVN

Longeveron

$5.96 /

-0.17 (-2.77%)

Cash and short-term…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LGVN Longeveron
$5.96 /

-0.17 (-2.77%)

LGVN Longeveron
$5.96 /

-0.17 (-2.77%)

03/24/22 Maxim
Maxim starts Longeveron at Buy, sees stock as 'inexpensive later-stage play'
03/24/22 Maxim
Longeveron initiated with a Buy at Maxim
01/05/22 EF Hutton
Longeveron initiated with a Buy at EF Hutton
LGVN Longeveron
$5.96 /

-0.17 (-2.77%)

LGVN Longeveron
$5.96 /

-0.17 (-2.77%)

Downgrade
ResMed downgraded to Neutral at Citi on valuation » 08:04
08/12/22
08/12
08:04
08/12/22
08:04
RMD

ResMed

$241.21 /

-2.37 (-0.97%)

Citi analyst John…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RMD ResMed
$241.21 /

-2.37 (-0.97%)

RMD ResMed
$241.21 /

-2.37 (-0.97%)

06:33 Today RBC Capital
ResMed downgraded to Sector Perform at RBC Capital on valuation
06:18 Today RBC Capital
ResMed downgraded to Sector Perform from Outperform at RBC Capital
06:18 Today Citi
ResMed downgraded to Neutral from Buy at Citi
06/06/22 RBC Capital
ResMed upgraded to Outperform from Sector Perform at RBC Capital
RMD ResMed
$241.21 /

-2.37 (-0.97%)

RMD ResMed
$241.21 /

-2.37 (-0.97%)

Earnings
VYNE Therapeutics reports Q2 adjusted EPS (13c) vs (35c) last year » 08:04
08/12/22
08/12
08:04
08/12/22
08:04
VYNE

VYNE Therapeutics

/

+

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VYNE VYNE Therapeutics
/

+

VYNE VYNE Therapeutics
/

+

08/10/22 H.C. Wainwright
VYNE Therapeutics price target lowered to $1.50 from $7 at H.C. Wainwright
01/13/22 Roth Capital
Roth raises Journey Medical target to $17 after dermatology assets acquisition
12/06/21 H.C. Wainwright
VYNE Therapeutics assumed with a Buy at H.C. Wainwright
08/13/21 Northland
VYNE Therapeutics price target lowered to $6 from $12 at Northland
VYNE VYNE Therapeutics
/

+

Earnings
Longeveron reports Q2 EPS (27c), consensus (23c) » 08:03
08/12/22
08/12
08:03
08/12/22
08:03
LGVN

Longeveron

$5.96 /

-0.17 (-2.77%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LGVN Longeveron
$5.96 /

-0.17 (-2.77%)

LGVN Longeveron
$5.96 /

-0.17 (-2.77%)

03/24/22 Maxim
Maxim starts Longeveron at Buy, sees stock as 'inexpensive later-stage play'
03/24/22 Maxim
Longeveron initiated with a Buy at Maxim
01/05/22 EF Hutton
Longeveron initiated with a Buy at EF Hutton
LGVN Longeveron
$5.96 /

-0.17 (-2.77%)

LGVN Longeveron
$5.96 /

-0.17 (-2.77%)

Recommendations
Oppenheimer says Leafly valuation 'beginning to look attractive' » 08:02
08/12/22
08/12
08:02
08/12/22
08:02
LFLY

Leafly

$2.25 /

-0.15 (-6.25%)

Oppenheimer analyst Jason…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LFLY Leafly
$2.25 /

-0.15 (-6.25%)

LFLY Leafly
$2.25 /

-0.15 (-6.25%)

07:32 Today Cowen
Leafly price target lowered to $4 from $12 at Cowen
06:12 Today Benchmark
Leafly price target lowered to $6.50 from $12.00 at Benchmark
05/20/22 Cowen
Cowen starts Leafly with Outperform with its early mover advantage
05/20/22 Cowen
Leafly initiated with an Outperform at Cowen
LFLY Leafly
$2.25 /

-0.15 (-6.25%)

LFLY Leafly
$2.25 /

-0.15 (-6.25%)

LFLY Leafly
$2.25 /

-0.15 (-6.25%)

Earnings
Crinetics reports Q2 EPS (81c), consensus (67c) » 08:02
08/12/22
08/12
08:02
08/12/22
08:02
CRNX

Crinetics

$20.58 /

-1.12 (-5.16%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CRNX Crinetics
$20.58 /

-1.12 (-5.16%)

CRNX Crinetics
$20.58 /

-1.12 (-5.16%)

06/15/22 Evercore ISI
Crinetics added to Best SMID 'Core' Ideas list at Evercore ISI
11/30/21 JMP Securities
Crinetics initiated with an Outperform at JMP Securities
11/23/21 Evercore ISI
Evercore starts 'rare endo treasure trove' Crinetics at Outperform
11/23/21 Evercore ISI
Crinetics initiated with an Outperform at Evercore ISI
CRNX Crinetics
$20.58 /

-1.12 (-5.16%)

  • 13
    Apr
  • 21
    Oct
CRNX Crinetics
$20.58 /

-1.12 (-5.16%)

Earnings
PepGen reports Q2 EPS ($1.23) vs ($6.03) last year » 08:01
08/12/22
08/12
08:01
08/12/22
08:01
PEPG

PepGen

$11.15 /

-0.27 (-2.36%)

Cash and cash equivalents…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PEPG PepGen
$11.15 /

-0.27 (-2.36%)

PEPG PepGen
$11.15 /

-0.27 (-2.36%)

05/31/22 Wedbush
PepGen initiated with an Outperform at Wedbush
05/31/22 Stifel
PepGen initiated with a Buy at Stifel
05/31/22 SVB Leerink
PepGen initiated with an Outperform at SVB Leerink
05/31/22 BofA
PepGen initiated with a Buy at BofA
PEPG PepGen
$11.15 /

-0.27 (-2.36%)

  • 06
    May
PEPG PepGen
$11.15 /

-0.27 (-2.36%)

Recommendations
System1 price target lowered to $19 from $26 at DA Davidson » 08:01
08/12/22
08/12
08:01
08/12/22
08:01
SST

System1

$8.69 /

+0.045 (+0.52%)

DA Davidson analyst Tom…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SST System1
$8.69 /

+0.045 (+0.52%)

SST System1
$8.69 /

+0.045 (+0.52%)

07:06 Today Benchmark
System1 price target lowered to $13 from $15 at Benchmark
07/11/22 BofA
BofA starts System1 at Buy with $12 price target
07/11/22 BofA
System1 initiated with a Buy at BofA
04/26/22 Evercore ISI
System1 initiated with an In Line at Evercore ISI
SST System1
$8.69 /

+0.045 (+0.52%)

SST System1
$8.69 /

+0.045 (+0.52%)

SST System1
$8.69 /

+0.045 (+0.52%)

Earnings
BIO-key sees 2022 revenue $10M-$13M » 08:01
08/12/22
08/12
08:01
08/12/22
08:01
BKYI

BIO-key

$2.15 /

+0.115 (+5.65%)

"BIO-key has built a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BKYI BIO-key
$2.15 /

+0.115 (+5.65%)

BKYI BIO-key
$2.15 /

+0.115 (+5.65%)

Downgrade
Wrap Technologies downgraded to Neutral from Buy at Ladenburg » 08:01
08/12/22
08/12
08:01
08/12/22
08:01
WRAP

Wrap Technologies

$2.07 /

+0.22 (+11.89%)

Ladenburg analyst Jon…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WRAP Wrap Technologies
$2.07 /

+0.22 (+11.89%)

WRAP Wrap Technologies
$2.07 /

+0.22 (+11.89%)

03/11/22 Ladenburg
Wrap Technologies price target lowered to $5.25 from $6.25 at Ladenburg
01/25/22 Maxim
Wrap Technologies downgraded to Hold at Maxim on management departures
01/25/22 Maxim
Wrap Technologies downgraded to Hold from Buy at Maxim
01/03/22 Ladenburg
Ladenburg uncovers 'significant loss' of future sales for Wrap Technologies
WRAP Wrap Technologies
$2.07 /

+0.22 (+11.89%)

Earnings
BIO-key reports Q2 EP (21c) vs. (15c) last year » 08:00
08/12/22
08/12
08:00
08/12/22
08:00
BKYI

BIO-key

$2.15 /

+0.115 (+5.65%)

Reports Q2 revenue $1.9M …

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BKYI BIO-key
$2.15 /

+0.115 (+5.65%)

BKYI BIO-key
$2.15 /

+0.115 (+5.65%)

Options
Apple put buyer realizes 14% same-day gains » 08:00
08/12/22
08/12
08:00
08/12/22
08:00
AAPL

Apple

$168.49 /

-0.73 (-0.43%)

Notable profits for the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AAPL Apple
$168.49 /

-0.73 (-0.43%)

AAPL Apple
$168.49 /

-0.73 (-0.43%)

08/11/22 Craig-Hallum
Enovix price target raised to $25 from $20 at Craig-Hallum
08/11/22 Loop Capital
Loop Capital has 'stronger conviction' in Enovix after 'customer milestones'
08/10/22 Bernstein
Apple Services performance fundamentally better than believed, says Bernstein
08/08/22 B. Riley
B. Riley thinks Globalstar's mystery satellite capacity customer is Apple
AAPL Apple
$168.49 /

-0.73 (-0.43%)

AAPL Apple
$168.49 /

-0.73 (-0.43%)

AAPL Apple
$168.49 /

-0.73 (-0.43%)

AAPL Apple
$168.49 /

-0.73 (-0.43%)

Recommendations
Roblox price target raised to $52 from $45 at Deutsche Bank » 07:56
08/12/22
08/12
07:56
08/12/22
07:56
RBLX

Roblox

$49.55 /

+1.52 (+3.16%)

Deutsche Bank analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
RBLX Roblox
$49.55 /

+1.52 (+3.16%)

RBLX Roblox
$49.55 /

+1.52 (+3.16%)

08/11/22 Wedbush
Roblox price target raised to $34 from $28 at Wedbush
08/10/22 Morgan Stanley
Roblox price target raised to $32 from $25 at Morgan Stanley
08/08/22 Truist
Roblox price target raised to $45 from $29 at Truist
08/01/22 MKM Partners
Roblox price target raised to $40 from $28 at MKM Partners
RBLX Roblox
$49.55 /

+1.52 (+3.16%)

RBLX Roblox
$49.55 /

+1.52 (+3.16%)

RBLX Roblox
$49.55 /

+1.52 (+3.16%)

RBLX Roblox
$49.55 /

+1.52 (+3.16%)

Recommendations
Oppenheimer encouraged as 'key initiatives taking hold' at CarMax » 07:56
08/12/22
08/12
07:56
08/12/22
07:56
KMX

CarMax

$101.64 /

+1.71 (+1.71%)

Oppenheimer analyst Brian…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KMX CarMax
$101.64 /

+1.71 (+1.71%)

KMX CarMax
$101.64 /

+1.71 (+1.71%)

07/14/22 Morgan Stanley
CarMax price target lowered to $124 from $140 at Morgan Stanley
06/27/22 RBC Capital
CarMax price target raised to $108 from $104 at RBC Capital
06/27/22 Wedbush
CarMax price target raised to $105 from $90 at Wedbush
06/27/22 Baird
CarMax valuation attractive for patient investors, says Baird
KMX CarMax
$101.64 /

+1.71 (+1.71%)

KMX CarMax
$101.64 /

+1.71 (+1.71%)

KMX CarMax
$101.64 /

+1.71 (+1.71%)

KMX CarMax
$101.64 /

+1.71 (+1.71%)

Recommendations
GeoPark price target lowered to $22 from $24 at Canaccord » 07:54
08/12/22
08/12
07:54
08/12/22
07:54
GPRK

GeoPark

$12.50 /

+0.55 (+4.60%)

Canaccord lowered the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GPRK GeoPark
$12.50 /

+0.55 (+4.60%)

GPRK GeoPark
$12.50 /

+0.55 (+4.60%)

Recommendations
ForgeRock price target raised to $20 from $15 at Deutsche Bank » 07:54
08/12/22
08/12
07:54
08/12/22
07:54
FORG

ForgeRock

$22.24 /

-1.13 (-4.84%)

Deutsche Bank analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FORG ForgeRock
$22.24 /

-1.13 (-4.84%)

FORG ForgeRock
$22.24 /

-1.13 (-4.84%)

07:39 Today Cowen
ForgeRock price target lowered to $25 from $28 at Cowen
07/13/22 Piper Sandler
ForgeRock price target raised to $25 from $24 at Piper Sandler
06/22/22 JPMorgan
ForgeRock price target lowered to $30 from $36 at JPMorgan
05/12/22 Deutsche Bank
ForgeRock price target lowered to $15 from $16 at Deutsche Bank
FORG ForgeRock
$22.24 /

-1.13 (-4.84%)

  • 16
    Sep
FORG ForgeRock
$22.24 /

-1.13 (-4.84%)

Recommendations
Privia Health price target raised to $51 from $36 at Guggenheim » 07:53
08/12/22
08/12
07:53
08/12/22
07:53
PRVA

Privia Health

$37.81 /

+1.42 (+3.90%)

Guggenheim analyst Sandy…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PRVA Privia Health
$37.81 /

+1.42 (+3.90%)

PRVA Privia Health
$37.81 /

+1.42 (+3.90%)

07:49 Today Canaccord
Privia Health price target raised to $45 from $40 at Canaccord
07:41 Today Cowen
Privia Health price target raised to $44 from $35 at Cowen
07/14/22 Truist
Privia Health price target raised to $40 from $36 at Truist
06/29/22 Canaccord
Privia Health price target raised to $40 from $29 at Canaccord
PRVA Privia Health
$37.81 /

+1.42 (+3.90%)

  • 19
    Nov
PRVA Privia Health
$37.81 /

+1.42 (+3.90%)

Recommendations
2seventy Bio price target lowered to $28 from $42 at Canaccord » 07:51
08/12/22
08/12
07:51
08/12/22
07:51
TSVT

2seventy Bio

$16.58 /

-0.66 (-3.83%)

Canaccord analyst John…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TSVT 2seventy Bio
$16.58 /

-0.66 (-3.83%)

TSVT 2seventy Bio
$16.58 /

-0.66 (-3.83%)

07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
05/02/22 Goldman Sachs
2seventy Bio initiated with a Buy at Goldman Sachs
02/10/22 SVB Leerink
SVB Leerink bullish on 2seventy Bio, initiates with an Outperform
02/10/22 SVB Leerink
2seventy Bio initiated with an Outperform at SVB Leerink
TSVT 2seventy Bio
$16.58 /

-0.66 (-3.83%)

TSVT 2seventy Bio
$16.58 /

-0.66 (-3.83%)

TSVT 2seventy Bio
$16.58 /

-0.66 (-3.83%)

Recommendations
Karuna Therapeutics price target raised to $330 from $200 at Guggenheim » 07:51
08/12/22
08/12
07:51
08/12/22
07:51
KRTX

Karuna Therapeutics

$261.01 /

+2.05 (+0.79%)

Guggenheim analyst Yatin…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
KRTX Karuna Therapeutics
$261.01 /

+2.05 (+0.79%)

KRTX Karuna Therapeutics
$261.01 /

+2.05 (+0.79%)

08/10/22 Wells Fargo
Karuna Therapeutics price target raised to $264 from $186 at Wells Fargo
08/09/22 Mizuho
Karuna Therapeutics price target raised to $276 from $190 at Mizuho
08/09/22 Citi
Zai Lab price target raised to $199 from $193 at Citi
08/09/22 BofA
Karuna Therapeutics price target raised to $261 from $160 at BofA
KRTX Karuna Therapeutics
$261.01 /

+2.05 (+0.79%)

  • 10
    Aug
  • 10
    Nov
KRTX Karuna Therapeutics
$261.01 /

+2.05 (+0.79%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.